Skip to main content

Advertisement

Table 3 Treatment response

From: Capecitabine in combination with either cisplatin or weekly paclitaxel as a first-line treatment for metastatic esophageal squamous cell carcinoma: a randomized phase II study

  Total (n = 94) CC (n = 46) CP (n = 48)
Best response    
Complete response 2 (2 %) 0 (0 %) 2 (4 %)
Partial response 52 (55 %) 26 (57 %) 26 (54 %)
Stable disease 22 (23 %) 10 (22 %) 12 (25 %)
Progressive disease 7 (7 %) 3 (7 %) 4 (8 %)
Not evaluable 11 (12 %) 7 (15 %) 4 (8 %)
Overall response rate 54 (57 %) 26 (57 %) 28 (58 %)
Disease control rate 76 (81 %) 36 (78 %) 40 (83 %)